US Patent Issued to Dana-Farber Cancer Institute, The General Hospital, University of Kansas on Feb. 24 for "Biomarkers predictive of cancer cell response to ML329 or a derivative thereof" (Massachusetts, Kansas Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,560,609, issued on Feb. 24, was assigned to Dana-Farber Cancer Institute Inc. (Boston), The General Hospital Corp. (Boston) and University of Kansas (Lawrence, Kan.).

"Biomarkers predictive of cancer cell response to ML329 or a derivative thereof" was invented by Rizwan Haq (Boston), David Fisher (Newton, Mass.) and Frank Schoenen (Lawrence, Kan.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is based in part on the identification of biomarkers, including NQO1, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof."

The patent was filed on Nov. 25, 2019, under Application No. 17/...